WuXi PharmaTech, China's largest CRO, boosted its revenue by 14.8% in the second quarter, as banner growth in its contract manufacturing business helped the company expand its global reach.
WuXi PharmaTech has increased its manufacturing capabilities in China, bolstering its fastest-growing business as it looks to expand around the globe.
More growth in its manufacturing operations helped pharma services company WuXi PharmaTech to another strong quarter.
China's WuXi PharmaTech has completed work on a biologics safety testing facility in Suzhou, adding 38,000 square feet of lab space to its sprawling presence in the area.
Chinese CRO WuXi PharmaTech notched another strong sales quarter, boosting its revenue by 11.3% thanks to escalating demand for its manufacturing services.
The rapidly expanding pharma services company WuXi PharmaTech started work on a new facility in Philadelphia for manufacturing cell therapies last month. Now it says it is ready to undertake an expansion in China that will eventually triple its manufacturing capacity.
WuXi PharmaTech, China's largest CRO, is upping its capacity in its two largest markets, wrapping up an expansion of a U.S. early-stage operation and breaking ground on an R&D campus outside of Shanghai.
Chinese outsourcing giant WuXi PharmaTech passed an FDA audit at one of its local facilities and broke ground on a new plant in the U.S., executing on its two-pronged strategy to take a bigger share of the global drug development market.
Chinese pharma services company WuXi PharmaTech reported 15% growth last year and said it expected to see similar growth this year. To maintain its momentum, the company has kicked off construction on a new facility in Philadelphia that will help achieve its expansion goals.
Chinese CRO WuXi PharmaTech has convinced Steve Yang, head of Asian R&D for AstraZeneca, to jump ship, joining the company as it looks to expand its presence in its home country and abroad.